



US009636405B2

(12) **United States Patent**
Tamarkin et al.

(10) **Patent No.:** **US 9,636,405 B2**
(45) **Date of Patent:** **May 2, 2017**

(54) **FOAMABLE VEHICLE AND
PHARMACEUTICAL COMPOSITIONS
THEREOF**

(71) Applicant: **Foamix Pharmaceuticals Ltd.,**
Rehovot (IL)
(72) Inventors: **Dov Tamarkin,** Maccabim (IL); **Doron**
Friedman, Karmeï Yosef (IL); **Meir**
Eini, Ness Ziona (IL); **Alex Besonov,**
Rehovot (IL)
(73) Assignee: **FOAMIX PHARMACEUTICALS**
LTD., Rehovot (IL)
(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 37 days.
(21) Appl. No.: **13/793,893**
(22) Filed: **Mar. 11, 2013**
(65) **Prior Publication Data**
US 2013/0189193 A1 Jul. 25, 2013

Related U.S. Application Data

(63) Continuation of application No. 13/708,284, filed on
Dec. 7, 2012, now abandoned, which is a continuation
of application No. 12/767,511, filed on Apr. 26, 2010,
now Pat. No. 8,362,091, which is a continuation of
application No. 11/430,599, filed on May 9, 2006,
now Pat. No. 7,704,518, and a continuation-in-part of
application No. 10/835,505, filed on Apr. 28, 2004,
now Pat. No. 7,820,145.

(60) Provisional application No. 60/679,020, filed on May
9, 2005, provisional application No. 60/784,793, filed
on Mar. 21, 2006, provisional application No.
60/530,015, filed on Dec. 16, 2003, provisional
application No. 60/492,385, filed on Aug. 4, 2003.

(51) **Int. Cl.**
A61K 47/10 (2017.01)
A61K 9/12 (2006.01)
A61L 9/01 (2006.01)
A61Q 19/00 (2006.01)
A61K 8/04 (2006.01)
A61K 9/00 (2006.01)
A61K 47/14 (2017.01)
A61K 47/38 (2006.01)
A01N 25/16 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 47/10** (2013.01); **A01N 25/16**
(2013.01); **A61K 8/046** (2013.01); **A61K**
9/0014 (2013.01); **A61K 9/0034** (2013.01);
A61K 9/12 (2013.01); **A61K 9/122** (2013.01);
A61K 47/14 (2013.01); **A61K 47/38** (2013.01);
A61Q 19/00 (2013.01); **Y10S 514/945**
(2013.01)

(58) **Field of Classification Search**
CPC **A61K 47/10**; **A61K 8/046**; **A61K 9/0014**;
A61K 9/0034; **A61K 9/12**; **A61K 9/122**;
A61L 9/01; **A61L 9/042**; **A61Q 19/00**;
Y10S 514/945

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

1,159,250	A	11/1915	Moulton
1,666,684	A	4/1928	Carstens
1,924,972	A	8/1933	Beckert
2,085,733	A	7/1937	Bird
2,390,921	A	12/1945	Clark
2,524,590	A	10/1950	Boe
2,586,287	A	2/1952	Apperson
2,617,754	A	11/1952	Neely
2,767,712	A	10/1956	Waterman
2,968,628	A	1/1961	Reed
3,004,894	A	10/1961	Johnson et al.
3,062,715	A	11/1962	Reese et al.
3,067,784	A	12/1962	Gorman
3,092,255	A	6/1963	Hohman
3,092,555	A	6/1963	Horn
3,141,821	A	7/1964	Compeau
3,142,420	A	7/1964	Gawthrop
3,144,386	A	8/1964	Brightenback
3,149,543	A	9/1964	Naab
3,154,075	A	10/1964	Weckesser
3,178,352	A	4/1965	Erickson

(Continued)

FOREIGN PATENT DOCUMENTS

AU	198780257	9/1986
AU	782515	12/2005

(Continued)

OTHER PUBLICATIONS

Sorbitan esters [online] retrieved on Jul. 1, 2016 from: <http://www.drugfuture.com/chemdata/sorbitan-esters.html> 2 pages.*

Chapter 1 Meaning of HLB Advantages and Limitations 1980; 4
pages.*

Sreenivasan et al. (Journal of the American Oil Chemists Society.
1956;33:61-66).*

U.S. Appl. No. 60/815,948, filed Jun. 23, 2006, Tamarkin.

U.S. Appl. No. 60/818,634, filed Jul. 5, 2006, Friedman.

U.S. Appl. No. 60/843,140, filed Sep. 8, 2006, Tamarkin.

U.S. Appl. No. 61/248,144, filed Oct. 2, 2009, Tamarkin.

U.S. Appl. No. 61/322,148, filed Apr. 8, 2010, Tamarkin.

U.S. Appl. No. 61/363,577, filed Jul. 12, 2010, Eini.

(Continued)

Primary Examiner — Ernst V Arnold

(74) *Attorney, Agent, or Firm* — Finnegan, Henderson,
Farabow, Garrett & Dunner LLP.

(57) **ABSTRACT**

A hygroscopic pharmaceutical composition includes at least one hygroscopic substance at a concentration sufficient to provide an *A_w* value of less than 0.9 or about 0.9 to about 0.7 and an anti-infective agent. A foamable pharmaceutical carrier includes about 50% to about 98% of a polar solvent selected from the group consisting of a polyol and PEG; 0% to about 48% of a secondary polar solvent; about 0.2% to about 5% by weight of a surface-active agent; about 0.01% to about 5% by weight of at least one polymeric agent; and a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition.

25 Claims, 1 Drawing Sheet